Spots Global Cancer Trial Database for azacitidine
Every month we try and update this database with for azacitidine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | NCT00728520 | Acute Myeloid L... Elderly | Azacitidine | 60 Years - | Kansas City Veteran Affairs Medical Center | |
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery | NCT01207726 | Stage IA Non-Sm... Stage IB Non-Sm... | Azacitidine Entinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | NCT05365035 | Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Venetoclax Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT01636609 | Acute Myeloid L... High Risk Myelo... | Azacitidine Cytarabine Tosedostat | 60 Years - | M.D. Anderson Cancer Center | |
| Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | NCT00005598 | Myelodysplastic... | amifostine trih... azacitidine | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | NCT04128501 | Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related... | Azacitidine Venetoclax | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | NCT03217838 | Acute Myeloid L... | AZD2811 Azacitidine Venetoclax | 18 Years - 130 Years | AstraZeneca | |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | NCT05381038 | Solid Tumor Gastrointestina... Breast Cancer | QPOP CURATE.AI Azacitidine + d... Azacitidine + p... Azacitidine + i... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | NCT04964505 | Acute Myeloid L... | Azacitidine Uproleselan Venetoclax | 18 Years - | University of California, Davis | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer | NCT01105377 | Recurrent Colon... Recurrent Recta... Stage IV Colon ... Stage IV Rectal... | entinostat azacitidine laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05140811 | Acute Myeloid L... Myelodysplastic... | IMM01 Azacitidine | 18 Years - | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | NCT03338348 | Acute Myeloid L... Myelodysplastic... | Vosaroxin Azacitidine | 60 Years - | University of Ulm | |
| A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | NCT04980885 | Acute Myeloid L... | AK117 Azacitidine | 18 Years - | Akeso | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00948064 | Leukemia | Vorinostat Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | NCT03542266 | Previously Untr... | CC-486 Administ... CHOP Administra... | 18 Years - 80 Years | Weill Medical College of Cornell University | |
| A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia | NCT05736965 | AML, Adult | Selinexor Azacitidine Venetoclax | 18 Years - | Shanghai Tong Ren Hospital | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | NCT05155709 | Acute Myeloid L... | siremadlin venetoclax azacitidine | 18 Years - 99 Years | Novartis | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | NCT06085638 | Chronic Myelomo... | Azacitidine Tamibarotene Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | NCT02158936 | Thrombocytopaen... | Eltrombopag Azacitidine Placebo Placebo | 18 Years - | Novartis | |
| Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) | NCT01048034 | Myelodysplastic... Chronic Myelomo... | Azacitidine Erythropoetin | 18 Years - | Nordic MDS Group | |
| Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03745352 | Recurrent Acute... Refractory Acut... | Azacitidine Pevonedistat | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC. | NCT01928576 | Non-Small Cell ... Epigenetic Ther... | Azacitidine Entinostat Nivolumab CC-486 300 | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | NCT00443261 | Squamous Cell C... | Azacitidine Cisplatin | 18 Years - | University of Kansas Medical Center | |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | NCT04801797 | Acute Myeloid L... | Cytarabine Idarubicin Daunorubicin Liposomal dauno... Venetoclax Azacitidine | 18 Years - | Massachusetts General Hospital | |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | NCT03765541 | Relapsed or Ref... | Dexamethasone Amsacrine Cytarabine Azacitidine | 18 Years - | University Hospital, Toulouse | |
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | NCT00890929 | Acute Myeloid L... Adult Acute Mye... | Lenalidomide Azacitidine | 60 Years - | Stanford University | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | NCT00234000 | Leukemia Myelodysplastic... | arsenic trioxid... azacitidine | 18 Years - | Jonsson Comprehensive Cancer Center | |
| A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes | NCT03151304 | Myelodysplastic... | Pracinostat Azacitidine | 18 Years - | Helsinn Healthcare SA | |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients | NCT05823701 | Diffuse Large B... | Chidamide Azacitidine obinutuzumab Liposomal mitox... | 18 Years - | The First Affiliated Hospital of Soochow University | |
| Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant | NCT01390311 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Pre-DLI Salvage... Donor Leukocyte... | 18 Years - | Washington University School of Medicine | |
| Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome | NCT01599325 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01892371 | FLT3 Gene Mutat... FLT3 Internal T... Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Cytarabine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | NCT02447666 | Myelodysplastic... Leukemia, Myelo... | Azacitidine | 1 Month - 18 Years | Celgene | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | NCT02553941 | Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Secondary Myelo... | Azacitidine Ibrutinib | 18 Years - | University of California, Davis | |
| Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery | NCT01292083 | Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Triple-negative... | azacitidine laboratory biom... immunohistochem... polymerase chai... western blottin... nucleic acid se... therapeutic con... | 18 Years - | University of Southern California | |
| Azacitidine and Pembrolizumab in Pancreatic Cancer | NCT03264404 | Pancreas Cancer | Pembrolizumab Azacitidine | 18 Years - | Columbia University | |
| Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia | NCT01338337 | Myelodysplastic... | Azacitidine | 18 Years - | Asociación Andaluza de Hematología y Hemoterapia | |
| Study to Evaluate CCS1477 in Haematological Malignancies | NCT04068597 | Haematological ... Acute Myeloid L... Non Hodgkin Lym... Multiple Myelom... Higher-risk Mye... Peripheral T Ce... | CCS1477 Pomalidomide Dexamethasone Azacitidine Venetoclax | 18 Years - | CellCentric Ltd. | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase II Study of Maintenance With Azacitidine in MDS Patients | NCT00446303 | Leukemia, Myelo... Myelodysplastic... | Azacitidine | 18 Years - 85 Years | Groupe Francophone des Myelodysplasies | |
| A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia | NCT05587049 | Acute Myeloid L... | 18 Years - | AbbVie | ||
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04243785 | Acute Myeloid L... Myelodysplastic... | BTX-A51 Azacitidine | 18 Years - | Edgewood Oncology Inc. | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) | NCT01065129 | Myelodysplastic... | G-CSF Plerixafor Azacitidine | 18 Years - | Washington University School of Medicine | |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes | NCT00102687 | Myelodysplastic... | azacitidine | 18 Years - | Celgene | |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT02953561 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Avelumab Azacitidine Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes | NCT01342692 | MDS | Azacitidine Azacitidine ass... Azacitidine ass... Azacitidine ass... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | NCT04284787 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute... | Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax | 60 Years - | National Cancer Institute (NCI) | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute | |
| Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS | NCT02018926 | Myelodysplastic... | Mocetinostat Azacitidine | 18 Years - | Mirati Therapeutics Inc. | |
| A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome | NCT03486353 | Myelodysplastic... | FF-10501-01 Azacitidine | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes | NCT02508870 | Myelodysplastic... | Atezolizumab Azacitidine | 18 Years - | Hoffmann-La Roche | |
| Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | NCT04266301 | Myelodysplastic... Leukemia, Myelo... | Sabatolimab Azacitidine Placebo | 18 Years - | Novartis | |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT03047993 | Acute Myeloid L... Blasts 20-30 Pe... Blasts 20-30 Pe... Chronic Myelomo... High Risk Myelo... IPSS Risk Categ... Myelodysplastic... | Azacitidine Glutaminase Inh... | 18 Years - | M.D. Anderson Cancer Center | |
| AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | NCT05404906 | Acute Myeloid L... | Azacitidine Venetoclax Supportive care | 18 Years - 64 Years | The First Affiliated Hospital of Soochow University | |
| A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy | NCT04150029 | Acute Myeloid L... | MBG453 Venetoclax Azacitidine | 18 Years - | Novartis | |
| A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | NCT06387420 | ACUTE MYELOID L... | AK117 Azacitidine Venetoclax Placebo | 18 Years - | Akeso | |
| A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | NCT02677922 | Leukemia, Myelo... | AG-120 Azacitidine AG-221 | 18 Years - | Celgene | |
| Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT00392353 | Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Adult... Refractory Anem... | Azacitidine Laboratory Biom... Pharmacological... Vorinostat | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | NCT00352001 | Leukemia Myelodysplastic... | azacitidine lenalidomide | 18 Years - 120 Years | Case Comprehensive Cancer Center | |
| Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | NCT01700673 | Acute Myeloid L... Myelodysplastic... | Azacitidine Sargramostim | 6 Months - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) | NCT01065129 | Myelodysplastic... | G-CSF Plerixafor Azacitidine | 18 Years - | Washington University School of Medicine | |
| Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | NCT05376111 | T-cell Acute Ly... Recruiting | Venetoclax, Aza... | 15 Years - | The First Affiliated Hospital of Soochow University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
